Adding umbralisib to ibrutinib produced responses in MCL, CLLJanuary 10, 2019CLLMantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
MD Anderson–led alliance seeks to advance leukemia drug developmentJanuary 9, 2019Business of MedicineALLAMLCMLCLL
Armored CAR protects T cells, induces remissionsJanuary 4, 2019Cellular TherapyCLLAggressive LymphomasB Cell Lymphoma
Long-term side effects of CAR T cells mostly mildJanuary 4, 2019Cellular TherapyCLLAggressive LymphomasB Cell Lymphoma
Ibrutinib-rituximab ‘new standard of care’ in younger CLL patientsDecember 11, 2018CLLAggressive Lymphomas
2018: A banner year for hematology drug approvalsDecember 5, 2018Business of MedicineCLLAggressive LymphomasMixed Topics
CLL resistance mechanism to venetoclax identifiedDecember 5, 2018CLLAggressive LymphomasB Cell Lymphoma
Cortactin expression aids in CLL-MCL differentialNovember 28, 2018CLLMantle Cell LymphomaAggressive Lymphomas
ASH 2018 coming attractions look at the big pictureNovember 21, 2018Aggressive LymphomasMultiple MyelomaCLLAnemiaMixed TopicsB Cell Lymphoma
